BiotechTube

Rifaximin 550 MG Oral Tablet [XIFAXAN]

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Pouchitis

Conditions

Pouchitis

Trial Timeline

Jul 1, 2024 → Jul 1, 2026

NCT ID
NCT06312683

About Rifaximin 550 MG Oral Tablet [XIFAXAN]

Rifaximin 550 MG Oral Tablet [XIFAXAN] is a approved stage product being developed by Bausch Health for Pouchitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06312683. Target conditions include Pouchitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06312683ApprovedRecruiting

Competing Products

3 competing products in Pouchitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyApproved
85
Liraglutide Pen Injector + Placebo Pen InjectorNovo NordiskPhase 2
51
etrasimod + PlaceboPfizerPhase 2
51

Other Products from Bausch Health

nabiloneApproved
80
High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foamApproved
80
benzoyl peroxide wash + Tretinoin gelApproved
80
Adapalene Gel + Tretinoin GelApproved
80
Omeprazole/sodium bicarbonateApproved
80